The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1172-1177 , November 2007

The natural history of IgE-mediated cow's milk allergy

Received 21 May 2007 ,Revised 8 August 2007 ,Accepted 8 August 2007.

  • Image Result

    CMA resolution over time. Kaplan-Meier survival curves for development of tolerance to cow's milk over time using 3 definitions for tolerance. The black line is the survival curve for criteria 1, the

    CMA resolution over time. Kaplan-Meier survival curves for development of tolerance to cow's milk over time using 3 definitions for tolerance. The black line is the survival curve for criteria 1, the red line is the survival curve for criteria 2, and the blue line is the survival curve for criteria 3.

  • Image Result
    Trend in cm-IgE levels over time by final CMA status. Scatter plots of all cm-IgE levels recorded, by age, to age 18 years (n = 2498). A, All values in the group with persistent CMA (n = 1651). B, All

    Trend in cm-IgE levels over time by final CMA status. Scatter plots of all cm-IgE levels recorded, by age, to age 18 years (n = 2498). A, All values in the group with persistent CMA (n = 1651). B, All values in the group with resolved CMA (n = 847). Nonparametric smoothed curves show the trend in cm-IgE levels over time. These curves approximate the mean value at any given age.

  • Image Result
    Relationship of peak cm-IgE level to resolution of IgE-mediated CMA over the period of the first 18 years of life. Patients were stratified by peak cm-IgE level, and survival curves for each stratum o

    Relationship of peak cm-IgE level to resolution of IgE-mediated CMA over the period of the first 18 years of life. Patients were stratified by peak cm-IgE level, and survival curves for each stratum of peak cm-IgE level were plotted. The number of patients in each stratum was as follows: <2 kU/L (n = 162); 2-4.9 (n = 106); 5-9.9 (n = 85); 10-19.9 (n = 115); 20-49.9 (n = 107); 50+ (n = 229).

 Supported by National Institutes of Health Training Grant #5T32 AI07007 and the Eudowood Foundation.

 Disclosure of potential conflict of interest: R. A. Wood has consulting arrangements with Dey Pharmaceutical, has received grant support from Merck and Genentech, and is on the speakers' bureau for Dey, Merck, and Glaxo. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01589-8

doi: 10.1016/j.jaci.2007.08.023

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1172-1177 , November 2007